Dyskinesia Review H1 2015 Reports on Pipeline, Global Clinical Trials
17 Apr, 2015, 08:00 ET
DALLAS, April 17, 2015 /PRNewswire/ --
LifeScienceIndustryResearch.com adds Dyskinesia - Pipeline Review, H1 2015 and Dyskinesia Global Clinical Trials Review, H1, 2015 market research reports of 2015 to the healthcare and pharmaceuticals category of its research library.
The Dyskinesia - Pipeline Review, H1 2015 report provides an overview of the Dyskinesia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Dyskinesia Therapeutics Development and mentioned in this research include Adamas Pharmaceuticals, Inc., Addex Therapeutics Ltd, Advicenne Pharma, Amarantus Bioscience Holdings, Inc., Astraea Therapeutics, LLC, Auspex Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Catalyst Pharmaceutical Partners, Inc., Contera Pharma ApS, EpiVax, Inc., Heptares Therapeutics Ltd., Integrative Research Laboratories Sweden AB, Ipsen S.A., Medicure Inc., Medy-Tox Inc., Merz Pharmaceuticals GmbH, Neurim Pharmaceuticals Ltd, Neurocrine Biosciences, Inc., Neurolixis Inc., Novartis AG, Osmotica Pharmaceutical Corp., Otsuka Holdings Co., Ltd., Santhera Pharmaceuticals Holding AG, SciFluor Life Sciences, LLC, Synchroneuron Inc. , Targacept, Inc. and Upsher-Smith Laboratories, Inc. Along with data tables, following figures have been provided in this research:
Number of Products under Development for Dyskinesia, H1 2015
Number of Products under Development for Dyskinesia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Order a copy of Dyskinesia - Pipeline Review, H1 2015 report at http://www.lifescienceindustryresearch.com/purchase?rname=39452 .
The second report on Dyskinesia Global Clinical Trials Review, H1, 2015 provides elemental information and data relating to the clinical trials on Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyskinesia. Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each. Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type as well as listings of discontinued trials (suspended, withdrawn and terminated) are covered in this research.
Clinical trial overview of companies like Ipsen S.A., Neurocrine Biosciences, Inc., Allergan, Inc., Merz Pharma GmbH & Co. KgaA, Novartis AG, Auspex Pharmaceuticals, Inc., UCB S.A., Eisai Co., Ltd., E. Merck KG and Adamas Pharmaceuticals, Inc. are mentioned in this research. Additionally, top institutes and government organizations like National Institute of Neurological Disorders and Stroke, University Health Network, University of Florida, Oregon Health & Science University, Leiden University Medical Center, Rush University Medical Center, Seoul National University Hospital, Taoyuan Mental Hospital, University of Iowa and Vanderbilt University are also covered in the report.
Readers of this report will understand the dynamics of a particular indication in a condensed manner and get an abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more. The readers can also obtain discontinued trial listing for trials across the globe as well as espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies. Order a copy of this research at http://www.lifescienceindustryresearch.com/purchase?rname=39131 .
Explore more reports for healthcare industry as well as on the pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect with Us:
G+ / Google Plus: https://plus.google.com/112612135957880308475/about
RSS / Feeds: http://www.lifescienceindustryresearch.com/feed
SOURCE Life Science Industry Research
Share this article